Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cholic Acid (MT921) after a Subcutaneous Injection in the Submental Area to Humans

被引:1
|
作者
Chung, Hyewon [1 ]
Park, Jin-Woo [2 ,3 ]
Kim, Dai-Hyun [4 ]
Seo, Soo-Hong [4 ]
Kim, Kyoung-Ah
Lee, Woo-Shun [5 ]
Park, Ji-Young [2 ]
机构
[1] Korea Univ, Guro Hosp, Dept Clin Pharmacol & Toxicol, Seoul 08308, South Korea
[2] Korea Univ, Coll Med, Anam Hosp, Dept Clin Pharmacol & Toxicol, Seoul 02841, South Korea
[3] Korea Univ, Anam Hosp, Med Ctr, Dept Neurol, Seoul 02841, South Korea
[4] Korea Univ, Dept Dermatol, Coll Med, Seoul 02841, South Korea
[5] Medytox Inc, Seoul 06175, South Korea
关键词
cholic acid; pharmacokinetics; pharmacodynamics; clinical trial; DEOXYCHOLIC-ACID; BILE-ACIDS; METABOLISM; CRITERIA; ATX-101;
D O I
10.3390/ph14080830
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study aimed to explore pharmacokinetics, pharmacodynamics, and safety/tolerability of MT921, an injectable cholic acid, after a single subcutaneous administration to healthy volunteers. A randomized, double-blinded, placebo-controlled, single dose-ascending phase 1 study enrolled 24 subjects who were assigned to three groups (60 mg, 120 mg, and 150 mg) of MT921. Blood samples were obtained for a 24-h period before and after injecting MT921 to the submental fat area. Plasma concentrations of cholic acid and deoxycholic acid were determined for pharmacokinetic analysis. Levels of free fatty acid, triglyceride, and total cholesterol were measured for pharmacodynamic analysis. Safety and tolerability were assessed until 21 days post-dose. While systemic exposure to cholic acid tended to increase as the MT921 dose increased, pharmacokinetic profiles of deoxycholic acid were similar among dose groups without showing significant changes. Pharmacodynamic profiles were comparable when measured at baseline and post-dose. The most frequent adverse events were injection site pain and edema. All adverse drug reactions resolved without treatment. MT921 appeared to be well-tolerated after an injection to the submental area at a dose up to 150 mg. Systemic exposure to cholic acid increased as the dose increased. Blood lipid profiles and deoxycholic acid levels were not affected by MT921 treatment.
引用
收藏
页数:10
相关论文
共 7 条
  • [1] PHARMACOKINETICS, PHARMACODYNAMICS AND TOLERABILITY OF DA-3091 AFTER SUBCUTANEOUS INJECTION IN HEALTHY SUBJECTS.
    Rhee, S.
    Yi, S.
    Choi, Y.
    Jiang, F.
    Yoon, S.
    Cho, J.
    Yu, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S54 - S54
  • [2] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Recombinant Human Parathyroid Hormone after Single- and Multiple-Dose Subcutaneous Administration in Healthy Chinese Volunteers
    Liu, Yani
    Shi, Shaojun
    Wu, Jianhong
    Li, Zhongfang
    Zhou, Xingqin
    Zeng, Fandian
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (02) : 154 - 161
  • [3] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody® ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers.
    Abd-Elaziz, Khalid
    Kamphuisen, Pieter W.
    Lyssens, Christophe
    Reuvers, Mariska
    den Daas, Izaak
    Van Bockstaele, Femke
    Vercruysse, Kristof
    Ulrichts, Hans
    Baumeister, Judith
    Crabbe, Patricia
    Compernolle, Veerle
    Holz, Josefin-Beate
    [J]. BLOOD, 2009, 114 (22) : 439 - 440
  • [4] Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of the Novel Dual GIP/GLP-1 Agonist (RG7697) after Single Subcutaneous Administration in Healthy Subjects
    Portron, Agnes
    Jadidi, Shirin
    Sarkar, Neena
    Dimarchi, Richard
    Schmitt, Christophe
    [J]. DIABETES, 2017, 66 : A624 - A624
  • [5] A Randomized Study of the Relative Pharmacokinetics, Pharmacodynamics, and Safety of Alirocumab, a Fully Human Monoclonal Antibody to PCSK9, After Single Subcutaneous Administration at Three Different Injection Sites in Healthy Subjects
    Lunven, Catherine
    Paehler, Tobias
    Poitiers, Franck
    Brunet, Aurelie
    Rey, Jacques
    Hanotin, Corinne
    Sasiela, William J.
    [J]. CARDIOVASCULAR THERAPEUTICS, 2014, 32 (06) : 297 - 301
  • [6] Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects
    Portron, Agnes
    Jadidi, Shirin
    Sarkar, Neena
    DiMarchi, Richard
    Schmitt, Christophe
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1446 - 1453
  • [7] A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
    Choi, Jae Duk
    Baek, Seungjae
    Kim, Youngmin
    Eun, Kahee
    Kwon, Se Chang
    Morrow, Linda
    Hompesch, Marcus
    Kang, Jahoon
    [J]. DIABETES, 2019, 68